CoChat

Investigating Potential GLP-1 Receptor Agonists in Cyclopeptides from Pseudostellaria heterophylla, Linum usitatissimum, and Drymaria diandra, and Peptides Derived from Heterophyllin B for the Treatment of Type 2 Diabetes: An In Silico Study

Open access
Liao, Hui-Jun, Tzen, Jason T. C. · 2022 · Metabolites

The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.

Abstract

GLP-1 receptor agonists stimulate GLP-1R to promote insulin secretion, whereas DPP4 inhibitors slow GLP-1 degradation. Both approaches are incretin-based therapies for T2D. In addition to GLP-1 analogs, small nonpeptide GLP-1RAs such as LY3502970, TT-OAD2, and PF-06882961 have been considered as possible therapeutic alternatives. Pseudostellaria heterophylla, Linum usitatissimum, and Drymaria diandra are plants rich in cyclopeptides with hypoglycemic effects. Our previous study demonstrated the potential of their cyclopeptides for DPP4 inhibition. Reports of cyclic setmelanotide as an MC4R (GPCR) agonist and cyclic α-conotoxin chimeras as GLP-1RAs led to docking studies of these cyclopeptides with GLP-1R. Heterophyllin B, Pseudostellarin B, Cyclolinopeptide B, Cyclolinopeptide C, Drymarin A, and Diandrine C are abundant in these plants, with binding affinities of −9.5, −10.4, −10.3, −10.6, −11.2, and −11.9 kcal/mol, respectively. The configuration they demonstrated established multiple hydrogen bonds with the transmembrane region of GLP-1R. DdC:(cyclo)-GGPYWP showed the most promising docking score. The results suggest that, in addition to DPP4, GLP-1R may be a hypoglycemic target of these cyclopeptides. This may bring about more discussion of plant cyclopeptides as GLP-1RAs. Moreover, peptides derived from the HB precursor (IFGGLPPP), including IFGGWPPP, IFPGWPPP, IFGGYWPPP, and IFGYGWPPPP, exhibited diverse interactions with GLP-1R and displayed backbones available for further research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/metabo12060549

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (a) GLP-1R and the G-protein (PDB:6X19). (b) GLP-1 (red alpha helix, the original ligand of GLP-1R)/GLP-1R (transmembrane region) complex (PDB:6X18). (c) Important amino acid residues in the transmembrane region (TM1-7) of GLP-1R (PDB:6X19). Ser31, Tyr205, Gln234, Arg310, Arg190, Glu364, and Leu388, shown in orange, delineate the approximate boundaries of the active site. Asn300, Lys197, Tyr148, and Tyr145, shown in red, are the residues involved in the important hydrogen bonds and π–π interaction network in the middle section. Tyr220 and Gln221, shown in green, are located on ECL1. The labeling of these important amino acids is based on the related studies of GLP-1 agonists [7,21]. The amino acids marked on the vertical axis on both sides and the horizontal axis on the bottom can be used as reference axes for analyzing the configuration of GLP-1R agonists. TM2 can also serve as a reference axis for configurational analysis of GLP-1RAs.
Figure 1 (a) GLP-1R and the G-protein (PDB:6X19). (b) GLP-1 (red alpha helix, the original ligand of GLP-1R)/GLP-1R (transmembrane region) complex (PDB:6X18). (c) Important amino acid residues in the transmembrane region (TM1-7) of GLP-1R (PDB:6X19). Ser31, Tyr205, Gln234, Arg310, Arg190, Glu364, and Leu388, shown in orange, delineate the approximate boundaries of the active site. Asn300, Lys197, Tyr148, and Tyr145, shown in red, are the residues involved in the important hydrogen bonds and π–π interaction network in the middle section. Tyr220 and Gln221, shown in green, are located on ECL1. The labeling of these important amino acids is based on the related studies of GLP-1 agonists [7,21]. The amino acids marked on the vertical axis on both sides and the horizontal axis on the bottom can be used as reference axes for analyzing the configuration of GLP-1R agonists. TM2 can also serve as a reference axis for configurational analysis of GLP-1RAs.CC BY · PubMed Central
Figure 2 (a) UK1 (PDB:6X19; MW: 886 g/mol), (b) LY3502970 or V6G, OWL-833 (PDB:6XOX; MW: 883.0 g/mol), (c) TT-OAD2 (PDB:6ORV; MW: 929.7 g/mol), (d) PF-06882961 or UK4 (PDB:6X1A; MW: 555.6 g/mol), (e) LSN3160440 or QW7 (PDB:6VCB; MW: 480.43 g/mol).
Figure 2 (a) UK1 (PDB:6X19; MW: 886 g/mol), (b) LY3502970 or V6G, OWL-833 (PDB:6XOX; MW: 883.0 g/mol), (c) TT-OAD2 (PDB:6ORV; MW: 929.7 g/mol), (d) PF-06882961 or UK4 (PDB:6X1A; MW: 555.6 g/mol), (e) LSN3160440 or QW7 (PDB:6VCB; MW: 480.43 g/mol).CC BY · PubMed Central
Figure 3 Reference GLP-1R and MC4 (GPCR) complex (PDB file from RCSB Protein Data Bank). (a) Peptide 5/GLP-1R (PDB:5NX2); (b) LSN3160440 and GLP-1 in GLP-1R (PDB:6VCB); (c) TT-OAD2/GLP-1R (PDB:6ORV); (d) LY3502970 in GLP-1R (PDB:6XOX); (e) PF-06882961/GLP-1R (PDB:6X1A); (f) Setmelanotide/MC4R (PDB:7PIU).
Figure 3 Reference GLP-1R and MC4 (GPCR) complex (PDB file from RCSB Protein Data Bank). (a) Peptide 5/GLP-1R (PDB:5NX2); (b) LSN3160440 and GLP-1 in GLP-1R (PDB:6VCB); (c) TT-OAD2/GLP-1R (PDB:6ORV); (d) LY3502970 in GLP-1R (PDB:6XOX); (e) PF-06882961/GLP-1R (PDB:6X1A); (f) Setmelanotide/MC4R (PDB:7PIU).CC BY · PubMed Central
Figure 4 (a) DdC/GLP-1R (−11.9 kcal/mol), (b) HJ/GLP-1R (−9.7 kcal/mol).
Figure 4 (a) DdC/GLP-1R (−11.9 kcal/mol), (b) HJ/GLP-1R (−9.7 kcal/mol).CC BY · PubMed Central
Figure 5 (a) PA/GLP-1R (−8.1 kcal/mol), (b) Quercetin/GLP-1R (−7.8 kcal/mol).
Figure 5 (a) PA/GLP-1R (−8.1 kcal/mol), (b) Quercetin/GLP-1R (−7.8 kcal/mol).CC BY · PubMed Central
Figure 6 (a) HB/GLP-1R (−9.5 kcal/mol), (b) PB/GLP-1R (−10.4 kcal/mol).
Figure 6 (a) HB/GLP-1R (−9.5 kcal/mol), (b) PB/GLP-1R (−10.4 kcal/mol).CC BY · PubMed Central
Figure 7 (a) CLC/GLP-1R (−10.6 kcal/mol), (b) DmA/GLP-1R (−11.2 kcal/mol).
Figure 7 (a) CLC/GLP-1R (−10.6 kcal/mol), (b) DmA/GLP-1R (−11.2 kcal/mol).CC BY · PubMed Central
Figure 8 “Receptor–ligand interaction” of cyclopeptides from the three plants with GLP-1R. (a) HB; (b) PB; (c) CLA; (d) CLC; (e) DdC; (f) DdA; (g) DmA; (h) HJ.
Figure 8 “Receptor–ligand interaction” of cyclopeptides from the three plants with GLP-1R. (a) HB; (b) PB; (c) CLA; (d) CLC; (e) DdC; (f) DdA; (g) DmA; (h) HJ.CC BY · PubMed Central
Figure 9 (a) IFGGLPPPN4 (−8.9 kcal/mol), (b) IFGGLPPPPN5 (−9.6 kcal/mol).
Figure 9 (a) IFGGLPPPN4 (−8.9 kcal/mol), (b) IFGGLPPPPN5 (−9.6 kcal/mol).CC BY · PubMed Central
Figure 10 (a) IFGGWPPPN7 (−10.7 kcal/mol), (b) IFPGWPPPN11 (−11.0 kcal/mol).
Figure 10 (a) IFGGWPPPN7 (−10.7 kcal/mol), (b) IFPGWPPPN11 (−11.0 kcal/mol).CC BY · PubMed Central
Figure 11 (a) IFGGYWPPPN20 (−10.9 kcal/mol), (b) IFGYGWPPPPN21 (−11.7 kcal/mol).
Figure 11 (a) IFGGYWPPPN20 (−10.9 kcal/mol), (b) IFGYGWPPPPN21 (−11.7 kcal/mol).CC BY · PubMed Central
Figure 12 (a) IFPGWPPN10 (−10.4 kcal/mol), (b) IFPRWPPN13 (−10.4 kcal/mol).
Figure 12 (a) IFPGWPPN10 (−10.4 kcal/mol), (b) IFPRWPPN13 (−10.4 kcal/mol).CC BY · PubMed Central
Figure 13 “Receptor–ligand interaction” of IFGGLPPP-derived peptides with GLP-1R from DS Visualizer. (a) IFGGLPPPN4/GLP-1R; (b) IFGRGWPPPN17/GLP-1R; (c) IFGGWPPPN7/GLP-1R; (d) IFPGWPPPN11/GLP-1R; (e) IFGGYWPPPN20/GLP-1R; (f) IFGYGWPPPPN21/GLP-1R.
Figure 13 “Receptor–ligand interaction” of IFGGLPPP-derived peptides with GLP-1R from DS Visualizer. (a) IFGGLPPPN4/GLP-1R; (b) IFGRGWPPPN17/GLP-1R; (c) IFGGWPPPN7/GLP-1R; (d) IFPGWPPPN11/GLP-1R; (e) IFGGYWPPPN20/GLP-1R; (f) IFGYGWPPPPN21/GLP-1R.CC BY · PubMed Central
Figure 14 Molecular dynamics simulation. Vertical axis: RMSD (Å). Horizontal axis: number of frames.
Figure 14 Molecular dynamics simulation. Vertical axis: RMSD (Å). Horizontal axis: number of frames.CC BY · PubMed Central
Figure 15 DdC molecular dynamics simulation series with H-bond (red-line) trajectory tracing. Over the course of the dynamic simulation of DdC in GLP-1R, the configuration gradually changes. See images starting from (a) (RMSD = 0), through (b–i) to (j). As the RMSD increases, the original hydrogen bonds are weakened by the increase in bond length.
Figure 15 DdC molecular dynamics simulation series with H-bond (red-line) trajectory tracing. Over the course of the dynamic simulation of DdC in GLP-1R, the configuration gradually changes. See images starting from (a) (RMSD = 0), through (b–i) to (j). As the RMSD increases, the original hydrogen bonds are weakened by the increase in bond length.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 22

Metadata

Authors
Liao, H.-J., & Tzen, J. T. C.
Affiliations
National Chung Hsing University (TW)
Corresponding author
Liao, Hui-Jun
Venue
Metabolites
Publisher
MDPI AG
Published
2022-06-15
Volume
12
Issue
6
Pages
549
ISSN
2218-1989 (ISSN-L)
OpenAlex
W4283009481
Cited by
21
References
60
Citations by year
2026: 5 · 2025: 12 · 2024: 3 · 2023: 1
FWCI
2.16
Type
journal article
Language
en
Open access
Locations
  • Metabolites (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GLP-1 receptor agonists, cyclopeptides, type 2 diabetes, Pseudostellaria heterophylla, flax, DPP-4 inhibition, GLP-1 receptor, molecular docking, plant peptides, hypoglycemic activity, cyclic peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Investigating Potential GLP-1 Receptor Agonists in Cyclopeptides from Pseudostellaria heterophylla, Linum usitatissimum, and Drymaria diandra, and Peptides Derived from Heterophyllin B for the Treatment of Type 2 Diabetes: An In Silico Study. https://app.cochat.ai/papers/10.3390/metabo12060549
The paper
Liao, H.-J., & Tzen, J. T. C. (2022). Investigating Potential GLP-1 Receptor Agonists in Cyclopeptides from Pseudostellaria heterophylla, Linum usitatissimum, and Drymaria diandra, and Peptides Derived from Heterophyllin B for the Treatment of Type 2 Diabetes: An In Silico Study. Metabolites. https://doi.org/10.3390/metabo12060549

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.